José Miguel Sánchez

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text

Medicine, Genetics, Oncology +11

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

Reginald V. Lord, Jan Brabender, David R. Gandara et al. · PubMed · 2002 · 671 citations

Medicine, Molecular Biology, Oncology +14

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

Manuel Cobo, Dolores Isla, Bartomeu Massutí et al. · Journal of Clinical Oncology · 2007 · 442 citations · Full text

Medicine, Molecular Medicine, Oncology +10

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Miguel Tarón, Yukito Ichinose, Rafael Rosell et al. · Clinical Cancer Research · 2005 · 336 citations

Medicine, Oncology, Pharmacology +17